Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Taps Former Instrument Executive to be CTO

NEW YORK, Aug. 7 – Microfluidics startup Fluidigm has appointed Douglas Modlin to the position of chief technology officer and vice president of research and development, the company said on Tuesday.  

Modlin previously served as vice president of instrumentation technology research and development at Molecular Devices Corporation. He has also worked in various capacities at LJL BioSystems, Affymax, and Affymetrix.

Fluidigm, formerly known as Mycometrix, has developed a technique for building "lab-on-a-chip" technology using flexible rubber slabs that can efficiently pump fluids through microscopic channels.

The technology has applications in cell sorting and mixing, and perhaps also in protein separation, sample preparation, and single molecule analysis.

In July, Fluidigm said that it would partner with Axon Instruments to develop a chip and instrument platform for handling and manipulating cells in experiments to learn how drug targets function in cells.

Fluidigm, based in South San Francisco, Calif., plans to release its chips commercially sometime in 2002, the company said.

Currently, it has developed starter kits that it sends to researchers, who in turn help the company develop new applications for the chips.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.